mRESVIA

Vaccine

Approvedregulatory verdict

Evidence outlook

Approved: Respiratory Syncytial Virus Infection

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
JP
  • Prevention of disease caused by RS virus infection
Product first approved 2025Outside this platform's coveragePMDA
EU
  • Protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection
Product first approved 2024biospace.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (4)
Other / comorbidity
NCT06067230 · ModernaTX, Inc.
2023-10-06 – 2026-07-24 · Respiratory Syncytial Virus
What this study did
NCT07117487 · ModernaTX, Inc.
2025-08-05 – 2026-03-27 · Respiratory Syncytial Virus
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT05127434 · ModernaTX, Inc.
2021-11-17 – 2025-07-28 · Respiratory Syncytial Virus
What this study did
Phase 2 (3)
Other / comorbidity
NCT06143046 · ModernaTX, Inc.
2023-11-15 – 2026-05-25 · Respiratory Syncytial Virus
What this study did
NCT05606965 · ModernaTX, Inc.
2022-11-02 – 2025-11-13 · Influenza
What this study did
NCT06097299 · ModernaTX, Inc.
2023-10-24 – 2025-06-27 · Respiratory Syncytial Virus
What this study did
Phase 1 (4)
Other / comorbidity
NCT05743881 · ModernaTX, Inc.
2023-02-15 – 2029-08-31 · Respiratory Syncytial Virus, Human Metapneumovirus
What this study did
NCT05397223 · ModernaTX, Inc.
2022-05-24 – 2026-02-27 · SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1 (1)
Other / comorbidity
NCT07764237 · ModernaTX, Inc.
2026-08-11 – 2027-07-20 · Respiratory Syncytial Virus (RSV), Human Metapneuomovirus (hMPV)
What this study did

Competitive landscape

This drug's own stage for Respiratory Syncytial Virus Infection: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
mRESVIA: this drugApprovedVaccineRSV pre-F proteinPartial signal
NCT05330975: Part A (mRNA-1345 with Afluria Quadrivalent vs mRNA-1345 alone), RSV-A day 29: GMT ratio 0.807 (95% CI 0.668 to 0.974), lower bound above 0.667, non-inferior; seroresponse difference -11.2% (95% CI -17.9 to -4.1), lower bound below -10%, non-inferiority not shown. Part B (with SARS-CoV-2 vaccine): RSV-A GMT ratio 0.796 (95% CI 0.702 to 0.901) and seroresponse difference -4.4% (95% CI -9.9 to 1.0), both non-inferior (CT.gov posted analyses).
Clesrovimab (Enflonsia)ApprovedMonoclonal antibodyRSV F proteinnot yet gradedNo reviewed efficacy summary in this indication
EDP-323Phase 2Small moleculeRSV L proteinPartial signal
NCT06170242: Quantitative Reverse Transcription-polymerase Chain Reaction (qRT-PCR): RSV Area Under the Viral Load-time Curve (VL-AUC) (Day 1 to Day 12): EDP-323 High Dose 99.05 log10 copies/mL*hours (Standard Deviation 133.325) | EDP-323 Low Dose 82.28 log10 copies/mL*hours (Standard Deviation 158.033) | Placebo 657.45 log10 copies/mL*hours (Standard Deviation 396.743)
ZelicapavirPhase 2Small moleculeRSV N protein (nucleoprotein)Weak signal
NCT05568706: Time to resolution of the four LRTD symptoms to mild (primary), zelicapavir 800 mg daily for 5 days vs placebo: median 5.0 vs 4.1 days (CT.gov), with no effect per the sponsor. Time to complete LRTD symptom resolution: 12.5 vs 13.0 days (mITT) and 12.0 vs 15.0 days (HR3), no test posted. missed
NCT04633187: Percentage of Subjects Who Develop Lower Respiratory Tract (LRTC) Complication (Day 1 through Day 28): EDP-938 0 Participants | Placebo 1 Participants
GSK5893818
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication
SP0256
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication
SP0291
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication
SP0340
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication
SP0341
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow mRESVIA to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
August 2029 (1)
Phase 1Respiratory Syncytial Virus, Human MetapneumovirusActive not recruiting
Est. primary completion 2029-08-31 · NCT05743881 · CT.gov ↗
What to watch

See the full readout calendar ↗